PRESS RELEASE published on 03/10/2025 at 21:09, 1 year 3 months ago Sanofi: Disclosure of trading in own shares
PRESS RELEASE published on 03/10/2025 at 21:09, 1 year 3 months ago Sanofi : Déclaration des transactions sur actions propres
BRIEF published on 03/08/2025 at 19:05, 1 year 3 months ago Sanofi-Aventis Reports Positive Data for Dupixent in Bullous Pemphigoid Clinical Study Dupixent Type 2 Inflammation Bullous Pemphigoid Regulatory Review
BRIEF published on 03/08/2025 at 19:05, 1 year 3 months ago Sanofi-Aventis publie des données positives sur Dupixent dans le traitement de la pemphigoïde bulleuse Étude Clinique Dupixent Pemphigoïde Bulleuse Examen Réglementaire Inflammation De Type 2
PRESS RELEASE published on 03/08/2025 at 19:00, 1 year 3 months ago Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Positive pivotal data for Dupixent in bullous pemphigoid presented at AAD, showing significant disease remission and reduction in severity, itch, and medication use. Regulatory submissions under review in US and EU Dupixent Type 2 Inflammation Bullous Pemphigoid AAD Sustained Remission
BRIEF published on 02/25/2025 at 07:05, 1 year 4 months ago Sarclisa Gains Approval in Japan for Multiple Myeloma Treatment Multiple Myeloma Sarclisa Approval Sanofi Oncology Japan Healthcare IMROZ Study
BRIEF published on 02/25/2025 at 07:05, 1 year 4 months ago Sarclisa obtient l'approbation au Japon pour le traitement du myélome multiple Myélome Multiple Étude IMROZ Approbation De Sarclisa Sanofi Oncologie Système De Santé Au Japon
PRESS RELEASE published on 02/25/2025 at 07:00, 1 year 4 months ago Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Sarclisa approved in Japan for newly diagnosed multiple myeloma patients, offering new treatment options based on positive IMROZ phase 3 study results Oncology Japan Multiple Myeloma Sarclisa IMROZ Study
PRESS RELEASE published on 02/24/2025 at 21:27, 1 year 4 months ago Sanofi : Déclaration des transactions sur actions propres
PRESS RELEASE published on 02/24/2025 at 21:27, 1 year 4 months ago Sanofi: Disclosure of trading in own shares
Published on 06/26/2026 at 01:40, 9 hours 25 minutes ago UraniumX Announces DTC Eligibility for U.S. Traded Shares
Published on 06/25/2026 at 23:30, 11 hours 35 minutes ago Zeus North America Mining Corp. Signs Option Agreement to Acquire Mining Claims in Idaho
Published on 06/25/2026 at 22:30, 12 hours 35 minutes ago Fountain Asset Corp. Provides Corporate Update
Published on 06/25/2026 at 21:32, 13 hours 33 minutes ago BlackBerry Announces Election Results for the Company's Board of Directors
Published on 06/25/2026 at 15:30, 19 hours 35 minutes ago Silver Spruce Resources, Inc. Adds Mining, Energy, and Finance Development Expertise to the Board and Announces Director Resignation
Published on 06/26/2026 at 10:50, 14 minutes ago Indotek Group acquires remaining 53% stake in Auchan Hungary, assumes full ownership
Published on 06/26/2026 at 10:47, 18 minutes ago flatexDEGIRO accelerates its growth trajectory and expects to achieve its 2027 financial targets already in 2026, one year ahead of schedule
Published on 06/26/2026 at 10:44, 20 minutes ago EQS-Adhoc: flatexDEGIRO SE: Full-year 2026 guidance raised, financial targets originally set for 2027 expected to be achieved already in 2026, one year ahead of time
Published on 06/26/2026 at 10:30, 35 minutes ago Uniper and Skyborn Renewables sign offshore wind PPA
Published on 06/26/2026 at 10:25, 39 minutes ago Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Initial Sale Prices
Published on 06/26/2026 at 07:00, 4 hours 5 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 4 hours 5 minutes ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/25/2026 at 18:45, 16 hours 19 minutes ago Avis Financier Semestriel SFCMC au 30 avril 2026
Published on 06/25/2026 at 18:30, 16 hours 35 minutes ago Avis financier semestriel SIEHM au 30 avril 2026
Published on 06/25/2026 at 17:50, 17 hours 15 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS